Work

PPM3 Cost-Effectiveness of Axicabtagene Ciloleucel (AXI-CEL) VS Standard of Care for Adult Patients with Relapsed or Refractory Diffuse Large B-CELL Lymphoma in Sweden, Norway, Finland, and Denmark

Year: 2020

Type: article

Source: Value in Health

DOI: 10.1016/j.jval.2020.08.1720

Authors: K. Karampampa, E. Stene, F. Axelsen, R. Lyngaa, S. Vadgama, M. Jerkeman, A. Wilén-Koort, K. Wallace

Institutions: Gilead Sciences (United Kingdom), Lund University

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3112752008

FWCI: 0.637

Cites:

Cited by: 4

Related to: 10